President, Research and Development · Revolution Medicines, Inc. (RVMD)

Steve Kelsey

A named executive officer of Revolution Medicines in every fiscal year CompBrief holds from FY2019 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,262,469

Salary $464,210Stock awards $0

FY2019: $1,895,403

2nd of 3 named executive officers at Revolution Medicines by FY2020 total.

3 named officers on file for Revolution Medicines, FY2020

Steve Kelsey’s pay file — $29

  • 2 fiscal years of pay, line by line
  • RVMD’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Revolution Medicines’s whole pay program stands against its peers

  • Revolution Medicines’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RVMD→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2021 (DEF 14A).

Free

Get Steve Kelsey’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Steve Kelsey compensation by year

Revolution Medicines Summary Compensation Table · all 2 fiscal years held
In US dollars, as Revolution Medicines reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020
Salary$424,350$464,210
Bonus$0$0
Stock awards$0$0
Option awards$1,298,253$522,559
Non-equity incentive$170,800$273,700
Pension and deferred compensation$0$0
All other$2,000$2,000
Total$1,895,403$1,262,469

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Revolution Medicines, Inc. DEF 14A filed April 28, 2021, accession 0001193125-21-136993, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Revolution Medicines, Inc. filed document, accession 0001193125-21-136993. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2021.

$1.9M
$1.3M
FY19
FY20
SalaryNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU41,763$1,826,714—
RSU22,500$984,150—
RSU12,125$530,348—
RSU938$41,028—
Option42,438—$18.56
Option78,750—$26.50
Option146,169—$29.80
Option3,282—$42.45

Per the Outstanding Equity Awards at Fiscal Year-End table in Revolution Medicines, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Revolution Medicines’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Mark GoldsmithPresident and Chief Executive Officer$2,388,211
Steve Kelsey · this pagePresident, Research and Development$1,262,469
Margaret HornChief Operating Officer and General Counsel$1,257,950

The full Revolution Medicines compensation record

free company brief

This page is one person within Revolution Medicines's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Revolution Medicines proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Revolution Medicines's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Steve Kelsey's compensation dossier · One-time report. No refunds.